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Summary 
CD23 is expressed on a variety of haemopoietic ceils 
and displays pleiotropic activities in vitro. We report 
that in addition to CD21 and IgE, CD23 interacts specifl- 
tally with the CD1 1 b and CD1 lc, the a chains of the 82 
integrin adhesion molecule complexes CD1 1 b-CD18 
and CD1 lc-CD18, on monocytes. Full-length recombi- 
nant CD23 incorporated into fluorescent liposomes 
was shown to bind to COS cells transfected with cDNA 
encoding either CD1 1 b-CD18 or CD1 lc-CD18 but not 
with CD1 la-CD18. The interaction was specifically in- 
hibited by anti-CD1 1 b or anti-CD1 lc, respectively, and 
by anti-CD23 MAbs. The functlonal significance of this 
ligand pairing was demonstrated by triggering CD1 1 b 
and CDllc on monocytes with either recombinant 
CD23 or anti-CD1 1 b and anti-CD1 lc MAbs to cause a 
marked increase in nitrlte-oxidative products and pro- 
inflammatory cytokines (IL-l 8, IL-8, and TNFa). These 
CDSB-mediated activities were decreased by Fab frag- 
ments of MAbs to CD11 b, CDllc, and CD23 These 
results demonstrate that CD1 1 b and CD1 lc are recep 
tors for CD23 and that thls novel llgand pairing regu- 
lates important activities of monocytes. 
Introduction 
CD23, a low affinity receptor for immunoglobulin E (IgE) 
(Yukawa et al., 1987; Bonnefoy et al., 1987) belongs to 
the C-type lectin family (Kikutani et al., 1986) some mem- 
bers of which have been identified as adhesion molecules. 
CD23 is expressed on a wide variety of haemopoeitic cell 
types including B and T lymphocytes, follicular dendritic 
cells, monocytes, platelets, Langerhanscells, eosinophils, 
and natural killer (NK) cells (Delespesse et al., 1992). By 
means of its interaction with CD21 (Aubry et al., 1992) 
CD23 is implicated in a variety of biological activities, in- 
cluding cell-cell adhesion, regulation of IgE synthesis, 
germinal center Bcell survival, and histamine release from 
basophils (Bonnefoy et al., 1993). CD23 is also involved 
in B cell growth, prothymocyte maturation, myeloid precur- 
sor proliferation, inhibition of macrophage migration, and 
antigen presentation (Gordon, 1991); not all of these activi- 
ties can be attributed to the interaction of CD23 with IgE 
or CD21. Increased levels of CD23 have been reported 
in various chronic inflammatory diseases including rheu- 
matoid arthritis(Hellen et al., 1991) systemic lupuserythe- 
matosous (Bansal et al., 1992) inflammatory bowel dis- 
ease (Kaiserlian et al., 1993), Sjagren’s syndrome, and 
glomerulonephritis (Yano et al., 1992). 
These findings led us to investigate whether CD23 inter- 
acts with a new ligand. We report that CD23 also interacts 
specifically with the cell surface proteins CD11 b and 
CD1 lc, the a chains of the 82 integrin adhesion molecule 
complexes CD1 1 b-CD18 and CD1 lc-CD18, on human 
monocytes. This new ligand pairing causes a marked in- 
crease in nitrite (NO,-), oxidative products (HzOOn),and pro- 
inflammatory cytokines (interleukin-18 [IL-181, IL-6, and 
TNFa) production by monocytes. 
Results and Discussion 
CD23 Binds to Human Blood Monocytes 
To search for the existence of another receptor for CD23, 
total blood mononuclear cells were incubated with recom- 
binant full-length CD23 incorporated into fluorescent lipo- 
somes and analyzed by flow cytometry (Pochon et al., 
1992). A fraction (lo%-20% depending on the donor) 
bound CD23 liposomes(Figure 1 a), which wasthen shown 
by double staining to consist mainly of CDl4positive cells 
(i.e., monocytes). A weak binding of CD23 liposomes on 
resting blood B cells was observed through an interaction 
with CD21 (data not shown). To confirm that monocytes 
were able to bind CD23 liposomes, blood mononuclear 
cells were FACS sorted into CDl4positive and CD14 
negative populations. CD23 liposomes were shown to bind 
mainly to the CDlCpositive population (Figure la). 
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Figure 1. CD23 Binding to Blood Monocytes 
(a) CD23 liposomes bind to CDWpositive blood mononuclear cells. In 
the experiment presented here, 12% of peripheral blood mononuclear 
cells were stained with CD23 liposomes. Blood mononuclear cells were 
stained with anti-CD14 MAbfollowed by sheep FlTCtonjugated (Fab’)2 
antibodies to mouse IgG and IgM prior to FACS sorting into CD14- 
positive and CDlCnegative cell populations. Separated cells were 
then stained with CD23 liposomes or control (glycophorin A) liposomes 
and analyzed by FACS. 
(b) Apparent molecularweight of CD23affinity-purified blood monocyte 
proteins and immunoreactivity with an anti-CD1 lc MAb. Lysates of 
blood monocytes were affinity-purified on a BSA (lane 1) or CD23 
column (lane 2) eluted proteins separated on SDS-PAGE gels, and 
silver stained (lanes 1 and 2). CD23 affinity-purified proteins were 
transferred onto nitrocellulose and filters were incubated with either 
an isotype-matched antibody (lane 3) or with an anti-CD1 lc MAb (lane 
4), then with horseradish peroxidase-conjugated goat anti-mouse anti- 
body. M, markers are shown on the left. 
CD23 Binds to CD1 lb and CDllc 
on Human Monocytes 
Since monocytes were found to express neither mem- 
brane IgE nor CD21 (data not shown), the known ligands 
for CD23, we investigated whether monocytes express a 
different receptor for CD23. Monocytes were lysed and 
cell extracts purified over an affinity column coupled with 
recombinant solu ble CD23or bovine serum albumin (BSA) 
(as control). SDS-PAGE and silver staining analysis of the 
eluted material from the CD23 column revealed bands of 
around 60 and 160 kDa molecular mass (Figure 1 b, lane 
2) bands that were absent in the BSA-purified material 
(Figure 1 b, lane 1). Antibodies identifying antigens within 
this rangeof molecular mass and reported to beexpressed 
on monocytes were tested by FACS for their capacity 
to inhibit CD23 liposome binding to monocytes (Figure 
2). Anti-CD1 1 b and anti-CD1 lc monoclonal antibodies 
(MAbs) both inhibited CD23 liposome binding to mono- 
cytes, with varying degrees of potency (Figure 2). Anti- 
CD13, antiCD49d, anti-CD21 (not expressed on mono- 
cytes), and anti-CD1 1 a(the third member of the 62 integrin 
family of adhesion molecules) had no significant effect 
(Figure 2). Antibodies against MHC class I, class II, CD14, 
and CD45 all of which highly expressed on monocytes, 
were also tested for their effect on CD23 liposome binding. 
None, however, had any effect (data not shown). Anti- 
CD1 6 MAbs gave a partial inhibition of CD23 binding. This 
could be due either to steric hindrance or to the induction 
of aconformationalchangeintheCD11 bandCDllcmole- 
cules upon anti-CD16 Mab binding. The monocyte-derived 
proteins eluted from the CD23 affinity column were immu- 
noreactive with anti-CDllc (see Figure 1 b, lane 4) and 
anti-CD1 1 b (data not shown) antibodies. 
CD23 Binds to CD1 1 b-CD18 and 
CD1 lc-CD18 Transfectants 
To confirm that the a chains of CD1 1 b-CD1 6 and CD1 1 c- 
CD16 were receptors for CD23, full-length cDNAs encod- 
ing CD1 1 band CD1 lc were transiently cotransfected with 
CD18 cDNA into COS cells. Transfectants expressing 
CD1 1 b-CD16 and CD1 lc-CD18 were both shown to bind 
CD23 liposomes, in contrast with transfectants expressing 
CD1 1 a-CD1 6 (Figure 3). This might be explained by the 
higher degree of homology between CD1 1 b and CD1 lc 
when compared with their homology to CD1 1 a (Corbi et 
al., 1987, 1966; Larson et al., 1969). The specificity of the 
interaction was demonstrated by inhibiting CD23 liposome 
binding using anti-CD1 1 b, anti-CD1 lc, and anti-CD23 
MAbs. The same results were obtained using BHK cells 
expressing CDllb-CD16 and CDllc-CD16 (data not 
shown). As further proof of the specificity of the CD23 
interaction, activated blood monocytes from a leukocyte 
adhesion-deficiency patient, lacking 62 integrin expres- 
sion due to a mutation in the gene encoding the 6 subunit 
(Fischer et al., 1968), were unable to bind CD23 liposomes 
(data not shown). Together, these data demonstrate that 
CD23 interacts with CD1 1 b and CD1 lc on normal human 
monocytes and on transfectants. 
CD23 Binding to CD1 1 b and CD1 lc Is Inhibited 
by Factor X and Is Cation Dependent 
CD11 b and CDllc are adhesion molecules that parti- 
cipate in many cell-cell and cell-matrix interactions 
(Springer, 1990). The initial results of this study show that 
CD1 1 b-CD1 8 and CD1 1 c-CD1 6 may exhibit an additional 
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Figure 3. CD23 Binding to CD11 b-CD18 and CDllc-CD18 COS 
Transfectants 
CD23 liposomes bind to a chains of CD1 lb-CD18 and CD1 Ic-CD18 
on recombinant transfectants. cDNAs coding for CD1 la, CD1 1 b, and 
CD18 were transfected together with CD18 in COS-7 cells to get ex- 
pression of the 52 integrins at the cell surface. Controls were done 
with single chain transfections. COS cells were stained 48 hr after 
transfection with anti-CD1 la, anti-CD1 1 b, and anti-CD1 1 c MAbs or 
isotypematched MAbs (control), followed by FITC-labeled sheep anti- 
mouse antibody. Between 10%-i 5% of the cells were shown to ex- 
press CD1 1 a. CD1 1 b. CD1 lc, or CD1 8 by staining with the respective 
MAbs. Prior to staining with CD23 liposomes, CDIE-positive 
transfected COS cells were then FACS-sorted to increase the petcent- 
ageofcellsexpressing~2integrins.CDlla-CDl8,CDll~CDl8,and 
CD1 l&CD18 transfectants were then incubated with CD23 liposomes 
(histogram 2) or control (glycophorin A) liposomes (histogram 1). The 
specificity of CD23 interaction with CD1 1 b and CD1 lc was demon- 
strated by inhibition of CD23 liposome binding to CDllb-CDlE and 
CD1 lc-CD18 transfectants using anti-CD1 1 b (histogram 4) anti- 
CD23 (histogram 5). and anti-CD1 Ic (histogram 6) MAbs, respectively. 
No binding of CD23 liposomes was observed on CDlla-CD18 
transfectants and no effect of anti-CDlla MAb was found (histo- 
gram 3). 
Figure 2. Effect of a Panel of MAbs on CD23 
Binding to Blood Monocytes 
Anti-CDllb and antiCDllc MAbs decrease 
CD23 liposome binding to activated blood 
monocytes. Activated monocytes were incu- 
bated with CD23 liposomes in the presence of 
different MAbs (aCD) or isotypematched con- 
trols (CTRL) (all used at IO pg/ml). Cells were 
analyzed by FACS and mean fluorescence in- 
tensity (MFI) measured. Data of a representa- 
tive experiment are presented. MFI of cells 
stained with control liposomes was6.5 and with 
CD23 liposomes was 84.5. Percentage inhibi- 
tion using arithmetic linear MFI values is calcu- 
lated according to the following formula: 
Percent of inhibition = 
MF, ([CD23-llpol) - ([CD23-lips] + MAb) x ,oo 
(CD23-lipo) 
adhesive function by virtue of their ability to bind CD23. 
CD1 lb-CD18 and CD1 lc-CD18 have been reported to 
bind several ligands, including CD!%, fibrinogen, factor X, 
lipopolysaccharide (LPS), concanavalin A, and zymosan 
(Springer, 1990). CD23 seems to identify an epitope close 
or identical to factor X as observed by the capacity of factor 
X to inhibit in a dose-dependent manner CD23 liposome 
binding without affecting surface expression of CD1 1 b or 
CD1 1 con monocytes (Figure 4). None of the other ligands 
tested had any effect. CD23 may be acting as a C-type 
lectin in its interaction with CD1 1 b and CD1 lc. EDTA de- 
creases CD23 binding to monocytes (Figure 4) by chela- 
tion of Ca2+, which is necessary to CD23 binding, or by 
chelation of the divalent cations, which are necessary for 
the binding of ligands to CD1 1 b and CD1 lc (Altieri, 1991). 
In this context, addition of Ca2+ or Mn2+ resulted in a dose- 
dependent increase of CD23 binding to monocytes(Figure 
4), like fibrinogen or factor X (Altieri, 1991). CD23-CD11 bl 
CD1 1 c interaction seems to involve sugars, but not sialic 
acid, as observed by the capacity of tunicamycin, but not 
neuraminidase, to decrease CD23 binding to monocytes. 
Quantification of the number of binding sites for CD23 on 
activated monocytes was determined by FACS: 20,000 
CD23 molecules, 50,000 anti-CD11 b and 20,000 anti- 
CD1 1 c antibodies bound per activated blood monocyte. 
Those results indicate that CD23 does not bind to all 
CD1 1 band CD1 1 c molecules. This could be due to hetero- 
geneity in CD1 1 b and CD1 lc glycosylation, and sugars 
are critical for CD23 binding, as indicated by the tuni- 
camycin experiment (Figure 4). Moreover, the affinity of 
CD23 for CD1 1 b and CD1 1 c is too low to be determined 
accurately, inasmuch as 100 x more CD23 than antibod- 
ies to CD1 1 b and CD1 lc is required to achieve saturation. 
CD23 bears extracellularly a triplet of amino acids (Asp, 
Gly, Arg) (Kikutani et al., 1986) which in the reverse orien- 
tation is a common recognition site for the integrin recep- 
tors. Therefore, the effect of a polyclonal antibody directed 
against this tripeptide was tested for its capacity to inhibit 
CD23 binding to monocytes. No inhibition was observed, 
confirming the absence of inhibition obtained with fibrino- 
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Figure 4. Structural Characterization of CD23-CDll b and CD23- 
CD1 1 c Interaction 
(a) Involvement of sugars and divalent cations. Purified activated blood 
monocytes were treated or not with tunicamycin or with neuramini- 
dase. Cells were then incubated with CD23 liposomes or control lipo- 
somes in absence or presence of EDTA (top left), Ca2* or Mn” (top 
right). 
(b) FactorX does inhibit CD23 binding to monocytes. Purified activated 
blood monocytes were incubated with CD23 liposomes in absence or 
presence of factor X (bottom left). Inset, factor X-treated (plus) or 
untreated (minus) cells were stained with isotype-matched control anti- 
body (ctrl). anti-CD1 la, anti-CD1 1 b, and anti-CD1 lc (all at 10 &ml) 
followed by FlTCconjugated sheep anti-mouse antibody. Purified acti- 
vated blood monocytes were incubated with CD23 liposomes in pres- 
ence of fibrinogen, purified recombinant ICAM-1, LPS, human serum 
opsonized-zymosan, IgE, or polyclonal antibody to RGD peptide (bot- 
tom right). Cells were analyzed by FACS and MFI measured. Percent- 
age inhibition was calculated as in Figure 2. 
gen (Figure 4). IgE ,which is binding in the lectin domain 
of CD23 (Kikutani et al., 1986) partially inhibits CD23 bind- 
ing to monocytes (Figure 4). Those results indicate that 
CD23 would seem to be acting as a C-type lectin recogniz- 
ing partly sugar and protein structures, reminiscent of what 
was observed for CD23 interaction with CD21 (Aubry et 
al., 1994). 
Binding of CD23 to CD1 1 b and CD1 ic on Monocytes 
Increases Nitric Oxide, HsOS, IL-1 p, IL-6, 
and TNFa Production 
To evaluate the functional significance of the interaction 
of CD23 with CD1 1 b or CD1 1 c, we investigated whether 
CD23-CD11 b/CD1 lc interaction could trigger monocytes 
a 
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Figure 5. CD23 Binding to CD1 1 b and CD1 1 c Increases Nitrite Pro- 
duction and Oxidative Burst by Blood Monocytes 
Recombinant CD23 by binding to CD1 1 b and CD1 1 c specifically in- 
creases (a) the nitrite production and (b) the oxidative burst by mono- 
cytes. Monocytes were incubated in the absence or presence of recom- 
binant soluble CD23, anti-CD1 1 a, anti-CD1 1 b, anti-CD1 lc MAbs. 
(a) To assess the amount of NO produced, the culture supernatants 
were assayed for the stable end products of NO, NO*-, and NOa-. 
The specificity of CDP&mediated increase of NO,- production was 
demonstrated by inhibition of NO,- production by Fab fragments of 
antiCD23, anti-CDllb, antiCDllc MAbs and by inhibition with nitro 
arginine (N-Arg). 
(b) Activated monocytes were incubated with hydroethidine and ana- 
lyzed by FACS. Percentage increase in red fluorescence of stimulated 
monocytes is shown in comparison to untreated monocytes. MFI val- 
ues of monocytes alone were 159 f 10. Mean 2 SD values of six 
experiments are presented. Concanavalin A, which is known to induce 
a respiratory burst in monocytes, was used as a positive control. The 
specificity of theCD23 interaction with CD1 lb and CD1 lc was demon- 
strated by inhibition of CDPSmediated increase of Hh production 
by Fab fragments of anti-CD1 1 b, anti-CD1 lc, and anti-CD23 MAbs. 
to release proinflammatory mediators such as nitric oxide 
(NO), H202, and cytokines. Triggering of adherence- 
activated normal monocytes using recombinant soluble 
CD23, anti-CD1 1 b or anti-CD1 lc antibodies increased the 
generation of NOa-, indicating the activation of the NO 
pathway (Moncada et al., 1991). The effect of CD23 on 
nitrite production was inhibited by Fab fragments of anti- 
CD23, anti-CD1 1 b, anti-CD1 lc MAbs and by nitroarginin, 
a specific inhibitor of the NO synthase pathway (Figure 
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Figure 6. CD23 Binding toCDl1 bandCD1 lc Increases Proinflamma- 
tory Cytokine Production by Blood Monocytes 
Monocytes were incubated overnight in the absence or presence of 
recombinant soluble CD23, anti-CD1 la, anti-CD1 1 b, anti-CD1 1 c, anti- 
CD23 MAbs. concanavalin A, LPS, or PMA. Cytokines were measured 
in the culture supernatant by specific ELISA. The specificity of CD23 
interaction with CD1 1 b and CD1 lc was demonstrated by inhibition of 
CDPI-mediated increase of cytokine production by Fab fragments of 
anti-CD1 lb, anti-CDllc, and anti-CD23 MAbs. Mean f SD values 
of four experiments are presented. 
5a). The oxidative burst was also shown to be regulated 
through CD11 b and CDllc, since recombinant soluble 
CD23, anti-CD1 1 b, and anti-CD1 lc MAbs all caused oxi- 
dation of hydroethidine to ethidium bromide in monocytes. 
The specificity of the CD23 effect on the oxidative burst 
was demonstrated by using Fab fragments of anti-CD23, 
anti-CD1 1 b, and anti-CD1 lc MAbs (Figure 5b). This con- 
firms and extends the finding that anti-CD1 1 b MAbs in- 
duce an oxidative burst in monocytes (Trezzini et al., 
1991). CD23 binding to CD1 1 b and CD1 1 c was associated 
with an early specific Ca2+ flux in blood monocytes (data 
not shown). 
Since activated macrophages are an important source 
of proinflammatory cytokines, we evaluated the effect of 
recombinant soluble CD23 and of anti-CD11 b and anti- 
CDllc MAbs on the production of such cytokines by 
monocytes. Recombinant soluble CD23, anti-CD1 1 b, and 
anti-CD1 1 c MAbs were potent stimulators of IL-1 3, IL-6, 
and TNFa. Again, the specificity of this induction was dem- 
onstrated by using Fab fragments of anti-CD11 b, anti- 
CD1 lc, and anti-CD23 MAbs (Figure 6). Interestingly, IL-1 
and TNFa were potent inducers of CD23 liposome binding 
to monocytes (data not shown), suggesting a potential cy- 
tokine autocrine loop through CD1 1 b and CD1 1 c stimula- 
tion and regulation. Moreover, engagement of surface 
CD23 expressed on monocytes has been shown pre- 
viously to result in an increase of NO, free radicals, and 
cytokine production (Paul-Eugene et al., 1992). Therefore, 
the CD23-CD11 band CD23-CD11 c pairing could exacer- 
bate the inflammatory reaction by autocrine and paracrine 
stimulatory pathways. 
In view of the increased levels of CD23 reported in vari- 
ous inflammatory diseases including rheumatoid arthritis 
(Hellen et al., 1991), we have also studied the effect of a 
neutralizing antibody to CD23 in a murine collagen type II- 
induced arthritis model. Administration of IgG anti-CD23 
resulted in marked amelioration of established arthritis 
(Plater-Zyberk and Bonnefoy, 1995). One potential mech- 
anism of action of anti-CD23 antibody therapy could be 
by blocking the interaction between CD23 and CD11 b, 
CD1 lc, therefore decreasing the release of proinflamma- 
tory cytokines that are known to participate in the inflam- 
matory process. The recent generation of CD23deficient 
mice (Fujiwara et al., 1994; Stief et al., 1994; Yu et al., 
1994) will also permit to investigate the role of this mole- 
cule in inflammatory processes in vivo. 
We have shown that CD23 is a functional ligand for 
CD1 1 band CD1 lc and that the interaction between these 
two types of adhesion receptors is likely to have important 
roles in controlling a number of monocytic activities, cells 
that play a key role in the immune response. 
Experimental Procedures 
cells 
Blood mononuclear cells were separated into T cells, B cells, and 
monocytes. T and B cells were separated by rosetting with sheep red 
blood cells. Monocytes were enriched by Ficoll and overnight adher- 
ence to plastic at 37OC. 
For tunicamycin treatment, cells were cultured for 46 hr in complete 
medium (RPM 1640; Seromed, Berlin, Germany) supplemented with 
2 mM glutamine and 10% heat inactivated fetal catf serum (Flow Lab@ 
ratories, Irvine, Scotland) containing 10 pa/ml of tunicamycin (Boeh- 
ringer Mannheim, Mannheim, Germany). 
For neuraminidase treatment, cells were treated for 45 min at 37’C 
with neuraminidase 0.1 U/ml (Boehringer Mannheim). 
The binding of CD23 liposomes was compared on treated and non- 
treated cells by flow cytometry (FACStar Plus, Becton Dickinson, 
Erembodegem. Belgium). 
Mobs and Reagents 
Anti-CD1 la Mabs 25.3 and EB15 were obtained from lmmunotech 
(Luminy, France) and Serotec (Oxford, England). Anti-CD1 1 b Mab 44 
was from Serotec, mon.gran 1 was from Janssen (Beerse, Belgium), 
Leu-15 was from Becton Dickinson, and (Bear-l) was from Sera-Lab. 
Limited (Sussex, England). Anti-CD1 Ic Mabs 3.9 was from Serotec, 
SL9 was from Sera-Lab, and BU-15 was from The Binding Site (Bir- 
mingham, England). Anti-CD13 Mab SJI Dl, anti-CD16 Mab BL5, anti- 
CD23 Mab (MAb 25) and antiCD49d Mab (HPP.l)were from Immuno- 
tech. Anti-CD21 Mab BL13 was from Immunotech, OKB7 was from 
Ortho, and 811-33 was obtained from Professor I. C. M. MacLennan; 
HE5 was from American Type Culture Collection (ATCC). OKB7 was 
from Ortho Diagnostics System, Incorporated (Raritan, New Jersey). 
AntiCDl4, antiCD3, antiCDl6, and anti-CD20 Mabs were from Bec- 
ton Dickinson. Sheep fluorescein isothiocyante (FITQconjugated 
(Fab$ antibodies to mouse IgG and IgM were obtained from Bioart 
(Meudon. France). The isotype Mab controls were purchased from 
Becton Dickinson. 
Recombinant cytokines IL-I, IL-6, TNFa and, soluble CD23 were 
produced by Glaxo Institute for Molecular Biology and were devoided 
of LPS contamination (Pyrotell-kit&IL; SKAN, Base& Switzerland). 
IL-4 was purchased from Amersham International (Buckinghamshire, 
England). Phorbol myrisate acetate (PMA) and ionomycin were ob 
tained from Calbiochem (La Jolla, California). LPS was from Sigma 
(St Louis, Missouri). 
Affinity Purlficatlon 
Activated monocyies (5 x lq were washed once with phosphate- 
buffered saline (PBS) and homogenized (Bell@ in 50 ml of extraction 
buffer: 50 mM Tris-HCI, 1% w/v Triton X-100, 100 mM NaCI, 2 mM 
CaCh, 2 mM MgClr. 1 mM TLCK, 1 mM PMSF, 1 mM benzamidine, 
and 10 mM iodoacetamide (pH 8.0). The cell lysate was further incu- 
bated 80 min on ice to allow proper extraction and was centrifuged 1 
hr at 100 000 x g. The supernatant was first applied with constant 
recyclingat25ml/hrtoaBSA-affigel-15affinityresin (Bio-Rad Labora- 
tories, Glattbrugg, Switzerland) coupled with 2 mg BSA/ml resin to 
remove nonspecific binding. The flow-through of this column was then 
applied under the same conditions to a CD23-affigel-15 affinity resin 
(5 ml) coupled with 3 mg of recombinant sCD23 (25 kDa)/ml resin. 
The CD23 affinity resin was washed first with 100 ml of extraction 
buffer then with 100 ml of extraction buffer containing only 0.1% Triton 
X-100. The material was finally eluted from the CD23 column with 50 
mM Tris-HCI, 3 M NKSCN, 0.1 46 w/v Triton X-100, 2 mM CaC12, 
and MgCll (pH 8.0) and immediately dialysed extensively against the 
same buffer, omitting the NH,SCN. The eluate was concentrated about 
20-fold using a centrifugal concentrator Macrosep having a Iv cut off 
membrane (Filtron). All procedures were carried out at 4OC. 
Western Blotting Analysis 
The concentrated material was then analyzed on a 7.5% nonreducing 
SDS-PAGE and transfered onto a 0.45 pm nitrocellulose membrane 
(Bio-Rad Laboratories, Glattbrugg, Switzerland) according to the in- 
structions of the manufacturer. The membrane was first incubated 
either with an anti-CD1 lc or with an anti-CD1 1 b (Serotec) MAb at IO 
pg/ml in PBS and 0.05% Tween-20 and stained using a goat anti- 
mouse peroxidase conjugate (Kirkegaard and Perry, Gaithersburg, 
Maryland). The immunoreactive bands were finally detected using the 
enhanced chemiluminescence Western blotting technology on Hyper- 
film enhanced chemiluminescence (Amersham Rahn, Zurich, Swit- 
zerland). 
Flow Cytometric Analysls 
Llposome Slndlng Assays 
Cells were resuspended in liposome suspension diluted in 0.5% BSA. 
0.1 sodium azide, 2 mM CaCl*, 140 mM NaCI, 20 mM HEPES (pH 7) 
and incubated for 2 hr at 4OC (Pochon et al., 1992). 
lnhlbiflon of Llposome Binding 
Cells were incubated with CD23 liposomes or control liposomes in 
absence or presence of EDTA (5 mM), Ca- or MnH (l-l 0 mM). Purified 
activated blood monocytes were incubated with CD23 liposomes in 
absence or presence of factor X (0.1-10 U/ml; Sigma), fibrinogen (50 
pg/ml; Sigma), purified recombinant ICAM-I (produced in our labora- 
tory), LPS (1 pg/ml; Sigma), human serum opsonized zymosan (1 mg/ 
ml; Sigma), IgE (50 Kg/ml; The Binding Site, Birmingham)or polyclonal 
antibody to ROD peptide (l/500, ATCC). 
CD Sfaining 
Cells were incubated with diluted Mabs and sheep FlTC-conjugated 
anti-mouse antibodies diluted in PBS, 0.5% BSA, and 0.05% sodium 
azide. Cells (5,000 events/condition) were analyzed by FACS 
(Bonnefoy et al., 1987). 
Quanflflcafion of Blndlng Sites per Cell by FACS 
Cells were incubated with saturating concentrations of purified Z-Z- 
CD23 fusion protein (P. G. et al., unpublished data), anti-CD1 lb, or 
anti-CD1 lc followed by sheep FlTC-conjugated anti-mouse antibod- 
ies. The QIFI-beads (Dako, Glostrup, Denmark) have been used. A 
calibration curve was built and the mean fluorescence intensity (MFI) 
arbitrary units are transformed in binding sites/cell (Poncelet and Cara- 
yon, 1985). 
Tranefectlons 
cDNAs coding for CDlla (Larson et al., 1989) were recloned in 
pCDNA1 (Invitrogen, San Diego, California). cDNAs for CD1 1 b (Corbi 
et al., 1987)andCD18(Kishimotoet al., 1987)were recloned in pCDM8 
(Seed, 1987’). Aliquots (20 pg) of DNA were transfected in COS-7 cells 
(ATCC) by electroporation (280 V, 980 mFD) using a Gene Pulser 
device (BieRad, Richmond, California) and 0.4 cm cuvettes in 20 mM 
HEPES (pH 7.4). 180 mM NaCI. Cotransfections of CD1 1 a, CD1 1 b, 
or CD1 lc with CD18 were performed to get expression of the 82 inte- 
grins at the cell surface. Controls were done with single chain transfec- 
tions. Cells were harvested 48 hr after transfection. 
Measurement of Nltrlte and Oxklatlve Burst Productlon 
Monocytes were incubated for 4 days at 37OC (nitrite) or overnight 
(oxidative burst) in the absence or presence of recombinant soluble 
CD23 (Graber et al., 1992) (50 “g/ml), anti-CD1 la (clone 25.3), anti- 
CD1 1 b (clone 44), anti-CD1 lc (clone BU-15) MAbs (all at 10 &ml). 
To assess the amount of NO produced, the culture supematants were 
assayed for the stable end products of NO, NO*-, and NQ- according 
to Green et al. (1982). Inhibition was obtained with nitroarginine (NArg 
at 1 mM) (Sigma). For oxidatiie burst, activated monocytes were incu- 
bated with hydroethidine (Molecular probes, Eugene, Oregon) (0.3 rg/ 
ml) for 30 min at 37OC (Rothe and Valet, 1990) and analyzed by FACS. 
Monocytes that had undergone an oxidative burst show an increase 
of red fluorescence signals compared with untreated monocytes re- 
fleeting oxidation of hydroethidine to ethidium bromide (Lacal et al., 
1990). 
Meesurement of Cytoklno Productlon 
Blood monocytes were incubated overnight at 37OC in the absence or 
presence of recombinant soluble CD23 (50 “g/ml), anti-CD1 la (clone 
25.3). anti-CD1 1 b (clone 44), anti-CD1 lc (clone BU-15), antiCD23 
(MAb 25) MAbs, concanavalin A(Sigma) (all at IO pg/ml), LPS (1 “g/ml) 
(Sigma) or PMA(5 ng/ml)(Calbiochem, La Jolla, California). Cytokines 
were measured in the culture supernatant by specific enzyme-linked 
immunosorbent assay (ELISA). The ELlSAs limit of sensitivity is 0.05 
“g/ml for IL-18 (Ferrua et al., 1988). 0.01 “g/ml for TNFa (Medgenix, 
Biotechnie. Rungis, France), and <O.Ol “g/ml for IL-8 (Manie et al., 
1993). 
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